Pfizer – Page 2 – media

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS PROVIDES 2018 FINANCIAL GUIDANCE

Pfizer Inc. (NYSE: PFE) reported financial results for fourthquarter and full-year 2017 and provided 2018 financial guidance.
- Source: Pfizer
- 519
- February 21, 2018
Company Insight Pfizer
GSK, Pfizer lead in new global Twitter pharma influencer ranking

Tweeting to the top, GlaxoSmithKline and Pfizer tied for the No. 1 spot in the inaugural ranking of global pharma influencers by Owen Health. The U.K.-based healthcare marketing agency evaluated 22 pharma companies on authority, reach, activity, engagement and influence to rate the most and least adept when it comes to Twitter.
- Source: fiercepharma
- 624
- January 23, 2018
global pharma influencers GSK Pfizer
Pfizer, Foundation Medicine to develop companion diagnostics for oncology treatments

Pfizer has collaborated with Foundation Medicine for the development of companion diagnostics (CDx) for its oncology portfolio.
- Source: invitrodiagnostics.medicaldevices-business-review
- 627
- January 18, 2018
Company Insight oncology Pfizer
Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.

Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
- Source: globalenergymedia
- 543
- January 17, 2018
financing Natural products organic biomolecules Pfizer small molecule
Pfizer lines up an $830M alliance with Arvinas on protein degradation

Pfizer has signed on to fund the launch of a hunt for a slate of small molecules that can degrade proteins, a key therapeutic pathway that’s been playing a role in prostate cancer and other areas.
- Source: Endpts
- 489
- January 10, 2018
C4 Therapeutics Market Views Pfizer protein degradation
Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal

Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.
- Source: Biospace
- 526
- January 8, 2018
Genentech Pfizer pharmaceutical company PROTAC small molecule therapeutics
Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS
- Source: Reuters
- 500
- January 4, 2018
ALS Company Insight FDA Gene therapy Pfizer
U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration(FDA) said, adding another competitor to a growing class of treatments.
- Source: Reuters
- 685
- December 25, 2017
ertugliflozin Merk New Approvals Pfizer
OTC Viagra– Pfizer snags nod for nonprescription sales of the little blue pill for men in the U.K.

Pfizer has won a first approval for OTC Viagra. Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
- Source: Fiercepharma
- 556
- December 13, 2017
erectile dysfunction drug New Approvals OTC Viagra Pfizer
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 642
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.